Un meta-análisis del papel de los inhibidores de la proteína quinasa p38 activada por mitógeno en pacientes con artritis reumatoide

Clinical Rheumatology 2013 doi 10.1007/s10067-013-2340-1

The role of p38-MAPK inhibitors in treating RA is the subject of some debate. Li et al. therefore performed the first meta-analysis of the current data to evaluate the efficacy and safety of these compounds. The authors identified 3 papers, covering 4 RCTs, for analysis and the results showed that p38-MAPK inhibition achieves a better level of ACR20 improvement vs. placebo, but showed no meaningful difference in ACR50, DAS28 or CRP levels past week 12. Due to the inadequate number and quality of available studies and small overall population size, this paper should be considered exploratory with further study needed in this area.

Keywords:


LinkedIn